Individuals with blood group O have a higher bleeding risk than non-O blood groups. This
could be explained by the lower levels of FVIII and von Willebrand Factor (VWF) levels in O …

This issue of Clinical Chemistry and Laboratory Medicine includes a review by Meyer M.
Samama on the laboratory assessment of the new anticoagulant agents (1). This is a timely …

Mast cell–derived heparin proteoglycans (HEP-PG) reside in vascular tissue and serve as a
local antithrombotic. Heparin, as used clinically, is isolated from its protein backbone from …

ABSTRACT Introduction Factor XI (FXI) deficiency is associated with highly variable
bleeding, including excessive gynecologic and obstetrical bleeding. Since approximately …

Background: The direct oral anticoagulant rivaroxaban inhibiting specifically activated factor
X (FXa) causes delayed thrombin generation (TG) as measured by calibrated automated …

Atrial fibrillation (AF) is the most commonly occurring arrhythmia, and is a condition of both
significant clinical and economic importance. An antithrombotic agent is considered …

Hemostasis is a delicate, dynamic and intricate system, in which pro-and anti-coagulant
forces cooperate for either maintaining blood fluidity under normal conditions, or else will …

Background The aim of the present work was to compare sex differences in thrombin
generation and fibrin network characteristics in a young healthy population, and correlate …

Arrays of silicon nanowire field-effect transistors (Si NWFETs) were built to detect thrombin
(a model biomarker) electrically. The Si NWFETs were created using a conventional top …

Background: Tissue factor (TF) is the main in vivo initiator of the blood coagulation cascade.
Active circulating TF was detected on small, negatively charged membrane vesicles, the so …